Home / Health / Postpartum GLP-1 Use Rises Amidst Limited Research
Postpartum GLP-1 Use Rises Amidst Limited Research
2 Oct
Summary
- New mothers' GLP-1 prescriptions saw a 24-fold increase over seven years.
- Most mothers began GLP-1s 3-6 months after delivery, with highest rates in diabetic mothers.
- Limited safety data exists for GLP-1 use during breastfeeding and postpartum.
A significant increase in the prescription of GLP-1 medications for new mothers has been observed. Research indicates a 24-fold rise in these diabetes and weight loss drugs being prescribed after childbirth over a seven-year period. Data shows that most mothers initiated these medications between three to six months postpartum.
The study identified that women with type 2 diabetes had the highest prescription rates. Prescribing also rapidly increased among those who were obese or overweight before pregnancy, and substantially among those with gestational diabetes.
Despite the widespread use and known health benefits of GLP-1s, the effects of these drugs during the postpartum period and while breastfeeding have not been extensively studied. Experts note that limited safety data exists, raising questions about potential impacts on infant growth and development.
This trend mirrors similar increases reported in other countries, suggesting a global shift in postpartum medication practices. The surge in GLP-1 use in this critical population warrants further investigation to ensure maternal and infant well-being.
